AndrewTuckerKuykendallMD

Hematologic Oncology

Associate Member, Department of Malignant Hematology

Overview of Dr. Kuykendall

Dr. Andrew Kuykendall is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. He received his medical degree from University of Florida College of Medicine and has been in practice 5 years. He is one of 173 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 49 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in Oncology. He has more than 90 publications and over 500 citings.

Office
12902 Magnolia Drive
Tampa, FL 33612
Book by Phone+1(567) 339-3401

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2015 - 2018
University of South Florida MorsaniResidency, Internal Medicine, 2012 - 2015
University of Florida College of MedicineClass of 2012

Certifications & Licensure

FL State Medical License 2014 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Avapritinib With Decitabine in Patients With SM-AHN Start of enrollment: 2024 Mar 13
Recruiting
Phase 1
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) Start of enrollment: 2022 Mar 01
Recruiting
Phase 2
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) Start of enrollment: 2024 Jul 15
Not yet recruiting
Phase 1
Study of Canakinumab in Patients With Myelofibrosis Start of enrollment: 2022 Aug 02
Recruiting
Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis Start of enrollment: 2022 May 04
Recruiting
Phase 1
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Start of enrollment: 2021 Apr 12
Recruiting
Phase 3
Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Join now to see all

Publications & Presentations

PubMed

Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib.
Haifa Kathrin Al-Ali, Andrew T Kuykendall, Catherine E Ellis, Janardhan Sampath, Ruben Mesa
Cancers. 2024-12-04
1 citations
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Rami S Komrokji, Luca Lanino, Somedeb Ball, Jan P Bewersdorf, Monia Marchetti
The Lancet. Haematology. 2024-11-01
6 citations
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis.
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, Juan-Carlos Hernandez-Boluda, Prithviraj Bose
Blood. 2024-10-24

Abstracts/Posters

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Fedratinib Alleviates Symptoms, Reduces Spleen Volume in MDS, MPNsDecember 10th, 2024
Systemic Mastocytosis: Information for Patients and CaregiversAugust 26th, 2024
Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK InhibitorDecember 1st, 2022
Join now to see all